We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Kymab: Biotech Company that is ‘One to Watch’

Kymab: Biotech Company that is ‘One to Watch’

Kymab: Biotech Company that is ‘One to Watch’

Kymab: Biotech Company that is ‘One to Watch’

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Kymab: Biotech Company that is ‘One to Watch’ "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Kymab, the Cambridge-based antibodies-to-medicines company, is featured in the top ten of The Sunday Times Tech Track ‘Ones to Watch’ 2015 list.

The ranking recognises Kymab’s potential for rapid future sales growth and increasing international presence. The Sunday Times Hiscox Tech Track 100 ranks Britain’s 100 fastest growing private companies, based on sales over three years.

 With investment from Bill & Melinda Gates Foundation, Malin Corporation plc, the Wellcome Trust, and Woodford Patient Capital Trust plc, Kymab is using its unique antibody development platform in therapeutic development and vaccine discovery. Its current targets include autoimmune disease and cancers, as well as infectious disease, such as HIV and malaria. 

“I am delighted and very proud that the growth Kymab has made has been recognised by The Sunday Times Tech Track, a barometer for success,” says Professor Allan Bradley, Chief Technical Officer, who founded Kymab in 2009. “The healthcare and research partners we work with know that Kymab is achieving remarkable results; our investors know that we are performing extremely well.” 

Dr. David Chiswell Chairman and interim CEO added: “To be recognised for our business performance by inclusion in this highly regarded table is a significant achievement for our Company.” 

The recognition follows Kymab’s nomination in June 2015 for the Emerging Star award at the London Stock Exchange techMARK mediscience annual event which celebrates excellence within the life-sciences sector.